HSB-888

**HSB-888** is an unmarketed, preclinical Quatramer nanoparticle-based anticancer combination developed for pediatric osteosarcoma. Hillstream described it as a dual-loaded formulation comprising an iron-mediated cell death inducer and an ultra-low-dose next-generation anthracycline analogue, intended to combine ferroptosis-related tumor cell killing with anthracycline cytotoxicity while improving tumor delivery and tolerability. The program received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for osteosarcoma; an IND filing had been planned but no clinical trial or approved product has been identified. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1861657/000149315221018497/filename1.htm))